Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib as adjuvant therapy in EGFR-mutant NSCLC.

The Lancet. Respiratory medicine - 1 Nov 2018

Jassem Jacek

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cisplatin
Share to ErbB Receptors
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Quinazolines

Share to Vinorelbine

Source

Identifiers

PMID: 30150013
DOI: 10.1016/S2213-2600(18)30307-2

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib as adjuvant therapy in EGFR-mutant NSCLC.PMID 30150013Read ↗

Erlotinib as maintenance therapy shows PFS benefit for lung cancer patients with EGFR-mutated tumors.Semantic proximity Read ↗

Erlotinib in lung cancer.Semantic proximity Read ↗

Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.Semantic proximity Read ↗

Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.Semantic proximity Read ↗

Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.Semantic proximity Read ↗

Erlotinib in the first-line treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.Semantic proximity Read ↗

Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations.Semantic proximity Read ↗

Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer?Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC.Semantic proximity Read ↗

Adjuvant Targeted Therapy for Patients With Epidermal Growth Factor Receptor-Mutant Lung Cancer.Semantic proximity Read ↗

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.